Gossamer Bio (GOSS) News Today

Gossamer Bio, Inc. (NASDAQ: GOSS) is under pressure as a wave of securities-class-action notices and lead-plaintiff deadline reminders continues to hit the stock. These filings keep investor attention focused on allegations tied to the company’s earlier Phase 3 PROSERA trial failure, which remains the main catalyst behind the recent weakness in the shares.

• Negative Sentiment: Multiple law firms, including Faruqi & Faruqi, Rosen, The Gross Law Firm, Pomerantz, and others, reminded investors that the June 1 lead-plaintiff deadline is approaching in the pending Gossamer Bio securities class action. Article Title
• Negative Sentiment: Several updates specifically reference claims tied to the February 23 announcement that PROSERA missed its primary endpoint, reinforcing the market’s concern that the trial setback may have harmed shareholders. Article Title
• Neutral Sentiment: HC Wainwright, while maintaining a Buy rating and $5 price target, cut near-term EPS estimates for 2026 and slightly lowered some quarterly projections, suggesting weaker expected profitability ahead. Article Title
• Neutral Sentiment: The same analyst raised FY2027 EPS expectations modestly, which partially offsets the short-term estimate cuts but does little to change the near-term legal overhang. Article Title

Overall, Gossamer Bio (GOSS) appears to be trading lower mainly because of the ongoing securities litigation headlines and reminders of the failed late-stage trial, while analyst revisions add a mixed but still cautious backdrop.